Global high-tech leaders choose to increase their holdings in China

Global high-tech leaders choose to increase their holdings in China: Carl Zeiss AG. signed two contracts: to invest 30 million US dollars for setting up Carl Zeiss (China) Investment Co., Ltd. and another 30 million US dollars investment for setting up Carl Zeiss Medical Technology (Shanghai) Investment Co., Ltd.

Carl Zeiss AG. is a leading company in the manufacture of optical systems, industrial measuring instruments and medical equipment. They signed two contracts on 11th Feb 2022: to invest 30 million US dollars for setting up Carl Zeiss (China) Investment Co., Ltd. and another 30 million US dollars investment for setting up Carl Zeiss Medical Technology (Shanghai) Investment Co., Ltd.

 

Image removed.

Carl Zeiss' booth at the 3rd China International Import Expo (Image source: Carl Zeiss official Weibo)

Halma Group, a German listed company, is the world's leading supplier of integrated solutions for  the woodworking industry and woodworking workshop production. Based on its strong confidence in the Chinese market, they carried out a new round of strategic integration in China in 2021.

Image removed.

The booth of Haomag (China) Machinery Co., Ltd.

CINIC HOLDINGS LIMITED (Hong Kong) is a holding company specialising in high-performance chemical materials. It has set up two factories in Qingpu, Shanghai and Taixing, Jiangsu. They have committed to a total investment of 100 million US dollars, and planned to build the Asia-Pacific regional headquarters on a total of 58 acres of land in the Hangzhou Bay Development Zone of Fengxian District, Shanghai.

Image removed.

SINIC Shanghai Qingpu Factory (Source: SINIC official website)

KPMG is a global network of professional services members. In 1993, a representative office was established in Shanghai. At present, KPMG Shanghai covers a total of 6 entities with a total staff size of more than 3,000.

After the establishment of KPMG Digital Technology (Shanghai), it will be linked with  KPMGDigital Ignition Centre, based on the digital transformation of Shanghai city, serve the Yangtze River Delta, constantly expand the business development boundaries of KPMG China in Shanghai, and contribute to boosting the development of Shanghai's modern service industry and building the "Shanghai Service" brand.

Shanghai Jowell Technology Co., Ltd. is a wholly foreign-owned enterprise established in China by Jowell Global Co., Ltd., which is listed on NASDAQ in the United States. The company's registered capital is 58 million US dollars, and it has paid 24.839 million US dollars so far. As an e-commerce company, its main business is  to sell health care products, cosmetics and daily necessities online and offline in China.

Weimob Group is  is a listed enterprise on the Main Board of the Hong Kong Stock Exchange , mainly engaged in the provision of enterprise cloud business and marketing solutions. In 2021, Weimob Group actually increased its capital by RMB 2 billion for R&D investment and daily operations. In January 2022, Weimob won another bid for the land in Songnan Community, Baoshan District, Shanghai with RMB 320 million.

China's huge domestic demand market has made foreign companies pay more and more attention to high-end consumption and the big health market.

Image removed.

The flagship store of “SHANG XIA 上下" in Huaihai Middle Road, Shanghai (Photo source: Shanghai Huangpu WeChat official account)

Zai Lab (Shanghai) Co., Ltd. is an innovative biopharmaceutical company based in China and operating globally, dedicated to providing innovative drugs in the fields of cancer, autoimmunity and infectious diseases to patients in China and around the world. Headquartered in Shanghai in 2014, it has 8 operation centres around the world and more than 1,900 employees. The plan is to increase the capital by 100 million US dollars, which is mainly used for the upgrade of the R&D centre.

Allogene Overland(Shanghai) Co., Ltd. is also an innovative biopharmaceutical company. Yao Shuyuan, CEO of the company introduced that in 2021, they set up a corporate headquarter in the Lingang New Area, with a total investment of more than 250 million yuan. He said that the project is expected to be completed in mid-2022 and will become China's leading clinical development and commercial production base for general-purpose cell therapy products."Lingang New Area has given us good policy support in terms of raw material and equipment import, foreign exchange and employment, and we are full of confidence in the company's prospects.

Source: Shangguan News



Looking for something specific?